Vom 31.5 bis 3.6. läuft eine große Biotechkonferenz in Chicago, bei der viele Firmen präsentieren und dementsprechend in den Blickpunkt der Investoren geraten können. Anbei eine Auflistung von Firmen, die man beobachten sollte.
On To ASCO
The industry just keeps on going as the Biotechnology Index (BTK) made higher 52-week highs four consecutive trading days in a row. Today the industry is taking a little breather but that's a good thing.
However, many smaller individual stocks are continuing to make large gains.
Today's edition has been the culmination of many hours of intense research. We have looked at everycompany presenting at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago (May 31st - June 3rd). Our list of focus companies have changed quite a few times because the stocks have appreciated beyond what we feel is a reasonable risk to reward ratio.
We decided to not overwhelm our readers with too much information on each company because this edition would resemble an academic paper. The following is a list of stocks we feel that should benefit from the ASCO meeting:
Shares of Entremed (ENMD) have been red hot having gone from $1.07 per share on April 1st to today's close of at $3.42. The company was very smart in taking advantage of this good fortune by completing two equity deals raising a total of $19.25 million. This new cash infusion plus the $15 million they had in the bank means that capital is no longer a worry.
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Molecular Therapeutics A phase I study of 2-methoxyestradiol (2ME2) in patients with solid tumors Isis Pharmaceuticals (ISIS) has had a tough year when the company announced disappointing phase III results for their antisense cancer drug, Affinitak. However in classic fashion shares hit a bottom after the news and have bounced from $2.50 per share to today's closing price of $6.22. Isis looks to have much to say at ASCO and with $269.5 million in cash ($4.87 per share) the company should be at many future conferences.
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session Developmental Therapeutics Molecular Therapeutics Phase 2 trial of ISIS 2503, an antisense inhibitor of h-ras, in combination with weekly paclitaxel in the treatment of patients with metastatic breast cancer.
6/3/03 Tues. 8:00 AM 12:00 PM S101 Poster Discussion Gastrointestinal Cancer Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study
6/1/03 Sun. 10:00 AM 10:15 AM E Hall D1 Oral Presentation Non-Small-Cell Lung Cancer Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report
Kosan Biosciences (KOSN) is our favorite play for the ASCO meeting. We have done a considerable amount of research on this company and may publish our findings in an upcoming edition. Long term, this is one of the most exciting biotechs we have seen for quite some time. Their partnership with Roche have essentially cuts their quarterly burn rate to a net loss of $3.2 million for the most recent quarter. Cash currently stands at approximately $80 million dollars while shares closed the day at $7.11. We have taken a position in the company at $7.15 and $7.09 per share.
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Cytotoxic Chemotherapy KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies Seattle Genetics (SGEN) is close to hitting 52-week highs after declining consistently for the past six months. Like Entremed, Seattle has taken advantage by raising capital. On May 13 the company announced that it had entered into a definitive purchase agreement for the sale of $40 million of Series A convertible preferred stock and warrants to purchase common stock. This means that investment banking fees are to be generated and the possibility of some analyst coverage may not be far behind. Shares closed today at $4.90.
6/2/03 Mon. 8:00 AM 12:00 PM S101 Poster Discussion Developmental Therapeutics Immunotherapy Phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with advanced stage or metastatic nonsmall cell lung cancer (NSCLC)
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Immunotherapy A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel for the treatment of metastatic breast carcinoma
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Immunotherapy A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with hormone refractory prostate carcinoma (HRPC)
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Immunotherapy Pharmacokinetics, safety, and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies
The last company we are featuring is Vical (VICL). Shares of the company are rebounding nicely since hitting a low of $2.12 in March. Shares closed today at $4.10 and look to move higher if attending conferences means anything. The company will be presenting at ASCO as well as the American Society of Gene Therapy (6/4/2003 through 6/8/2003) and the Needham & Company Healthcare Conference (6/5/2003 3:00 PM ET).
5/31/03 Sat. 2:00 PM 5:30 PM S Hall A2 General Poster Session Melanoma A phase II study of high-dose allovectin-7 in patients with advanced metastatic melanoma.
All of the companies mentioned in this edition have appreciated considerably. It is inevitable that the sector pulls back and profit taking begins to slow the sector down. However, no one knows the longevity of this biotech rally but until something else takes center stage we will focus on opportunities in this industry.
Much thanks to many of our readers who have submitted biotech companies that they are bullish on.
chart.bigcharts.com/bc3/quickchart/...37&mocktick=1&rand=4471" style="max-width:560px" >
chart.bigcharts.com/bc3/quickchart/...82&mocktick=1&rand=4062" style="max-width:560px" >
chart.bigcharts.com/bc3/quickchart/...30&mocktick=1&rand=9258" style="max-width:560px" >
chart.bigcharts.com/bc3/quickchart/...87&mocktick=1&rand=7742" style="max-width:560px" >
chart.bigcharts.com/bc3/quickchart/...67&mocktick=1&rand=8201" style="max-width:560px" >
On To ASCO
The industry just keeps on going as the Biotechnology Index (BTK) made higher 52-week highs four consecutive trading days in a row. Today the industry is taking a little breather but that's a good thing.
However, many smaller individual stocks are continuing to make large gains.
Today's edition has been the culmination of many hours of intense research. We have looked at everycompany presenting at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago (May 31st - June 3rd). Our list of focus companies have changed quite a few times because the stocks have appreciated beyond what we feel is a reasonable risk to reward ratio.
We decided to not overwhelm our readers with too much information on each company because this edition would resemble an academic paper. The following is a list of stocks we feel that should benefit from the ASCO meeting:
Shares of Entremed (ENMD) have been red hot having gone from $1.07 per share on April 1st to today's close of at $3.42. The company was very smart in taking advantage of this good fortune by completing two equity deals raising a total of $19.25 million. This new cash infusion plus the $15 million they had in the bank means that capital is no longer a worry.
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Molecular Therapeutics A phase I study of 2-methoxyestradiol (2ME2) in patients with solid tumors Isis Pharmaceuticals (ISIS) has had a tough year when the company announced disappointing phase III results for their antisense cancer drug, Affinitak. However in classic fashion shares hit a bottom after the news and have bounced from $2.50 per share to today's closing price of $6.22. Isis looks to have much to say at ASCO and with $269.5 million in cash ($4.87 per share) the company should be at many future conferences.
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session Developmental Therapeutics Molecular Therapeutics Phase 2 trial of ISIS 2503, an antisense inhibitor of h-ras, in combination with weekly paclitaxel in the treatment of patients with metastatic breast cancer.
6/3/03 Tues. 8:00 AM 12:00 PM S101 Poster Discussion Gastrointestinal Cancer Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study
6/1/03 Sun. 10:00 AM 10:15 AM E Hall D1 Oral Presentation Non-Small-Cell Lung Cancer Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report
Kosan Biosciences (KOSN) is our favorite play for the ASCO meeting. We have done a considerable amount of research on this company and may publish our findings in an upcoming edition. Long term, this is one of the most exciting biotechs we have seen for quite some time. Their partnership with Roche have essentially cuts their quarterly burn rate to a net loss of $3.2 million for the most recent quarter. Cash currently stands at approximately $80 million dollars while shares closed the day at $7.11. We have taken a position in the company at $7.15 and $7.09 per share.
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Cytotoxic Chemotherapy KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies Seattle Genetics (SGEN) is close to hitting 52-week highs after declining consistently for the past six months. Like Entremed, Seattle has taken advantage by raising capital. On May 13 the company announced that it had entered into a definitive purchase agreement for the sale of $40 million of Series A convertible preferred stock and warrants to purchase common stock. This means that investment banking fees are to be generated and the possibility of some analyst coverage may not be far behind. Shares closed today at $4.90.
6/2/03 Mon. 8:00 AM 12:00 PM S101 Poster Discussion Developmental Therapeutics Immunotherapy Phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with advanced stage or metastatic nonsmall cell lung cancer (NSCLC)
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Immunotherapy A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel for the treatment of metastatic breast carcinoma
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Immunotherapy A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with hormone refractory prostate carcinoma (HRPC)
6/2/03 Mon. 9:00 AM 1:00 PM S Hall A2 General Poster Session
Developmental Therapeutics Immunotherapy Pharmacokinetics, safety, and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies
The last company we are featuring is Vical (VICL). Shares of the company are rebounding nicely since hitting a low of $2.12 in March. Shares closed today at $4.10 and look to move higher if attending conferences means anything. The company will be presenting at ASCO as well as the American Society of Gene Therapy (6/4/2003 through 6/8/2003) and the Needham & Company Healthcare Conference (6/5/2003 3:00 PM ET).
5/31/03 Sat. 2:00 PM 5:30 PM S Hall A2 General Poster Session Melanoma A phase II study of high-dose allovectin-7 in patients with advanced metastatic melanoma.
All of the companies mentioned in this edition have appreciated considerably. It is inevitable that the sector pulls back and profit taking begins to slow the sector down. However, no one knows the longevity of this biotech rally but until something else takes center stage we will focus on opportunities in this industry.
Much thanks to many of our readers who have submitted biotech companies that they are bullish on.
